[go: up one dir, main page]

MXPA05011521A - Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo. - Google Patents

Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.

Info

Publication number
MXPA05011521A
MXPA05011521A MXPA05011521A MXPA05011521A MXPA05011521A MX PA05011521 A MXPA05011521 A MX PA05011521A MX PA05011521 A MXPA05011521 A MX PA05011521A MX PA05011521 A MXPA05011521 A MX PA05011521A MX PA05011521 A MXPA05011521 A MX PA05011521A
Authority
MX
Mexico
Prior art keywords
difluoro
tetrahydro
salt
benzazepine derivative
derivative
Prior art date
Application number
MXPA05011521A
Other languages
English (en)
Inventor
Chikashi Saitoh
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MXPA05011521A publication Critical patent/MXPA05011521A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5H-1-benzazepina novedoso representado por la siguiente formula (I) o una sal farmaceuticamente aceptable del derivado. Estas son utiles como un agente terapeutico o preventivo para la polaquisuria nocturna y/o la diabetes insipida.
MXPA05011521A 2003-04-28 2004-04-26 Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo. MXPA05011521A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003123032 2003-04-28
JP2003401126 2003-12-01
PCT/JP2004/005998 WO2004096775A1 (ja) 2003-04-28 2004-04-26 ４，４－ジフルオロ－１，２，３，４－テトラヒドロ－５ｈ－１－ベンゾアゼピン誘導体又はその塩

Publications (1)

Publication Number Publication Date
MXPA05011521A true MXPA05011521A (es) 2006-01-23

Family

ID=33422056

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011521A MXPA05011521A (es) 2003-04-28 2004-04-26 Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.

Country Status (17)

Country Link
US (2) US7183271B2 (es)
EP (1) EP1619185B1 (es)
KR (1) KR100882154B1 (es)
AT (1) ATE512951T1 (es)
AU (1) AU2004234258B2 (es)
BR (1) BRPI0409718A (es)
CA (1) CA2521492C (es)
DK (1) DK1619185T3 (es)
IL (1) IL171332A (es)
MX (1) MXPA05011521A (es)
NO (1) NO333505B1 (es)
NZ (1) NZ542815A (es)
PL (1) PL1619185T3 (es)
PT (1) PT1619185E (es)
RU (1) RU2326868C2 (es)
SI (1) SI1619185T1 (es)
WO (1) WO2004096775A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2004096775A1 (ja) 2003-04-28 2004-11-11 Astellas Pharma Inc. ４，４－ジフルオロ－１，２，３，４－テトラヒドロ－５ｈ－１－ベンゾアゼピン誘導体又はその塩
NZ565080A (en) 2005-07-22 2011-03-31 Mochida Pharm Co Ltd Novel heterocyclidene acetamide derivative
CA2988753A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
JP5767103B2 (ja) * 2008-05-21 2015-08-19 フエリング・インターナシヨナル・センター・エス・アー 夜間頻尿によって妨げられない睡眠の初期期間を増加させるための口腔内崩壊デスモプレシン
SI2860175T1 (en) * 2012-06-11 2018-04-30 Tacurion Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepine compound and intermediate for synthesis thereof
CN109476645A (zh) 2016-07-14 2019-03-15 辉瑞大药厂 作为vanin-1酶抑制剂的新的嘧啶甲酰胺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684537B2 (en) 1993-08-26 1997-12-18 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
JP3215910B2 (ja) * 1994-06-15 2001-10-09 大塚製薬株式会社 ベンゾヘテロ環誘導体
JPH11349570A (ja) 1994-06-15 1999-12-21 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環誘導体
DE69535486T2 (de) 1994-06-15 2008-04-10 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclische Verbindungen verwendbar als Vasopressin- oder Oxytocin-Modulatoren
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
JPH09221475A (ja) 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
JP2926335B2 (ja) 1997-06-13 1999-07-28 大塚製薬株式会社 医薬組成物
NZ502448A (en) 1997-07-30 2002-12-20 Wyeth Corp Tricyclic vasopressin agonists and medicaments containing these compounds
SI1000062T1 (en) 1997-07-30 2004-12-31 Wyeth Tricyclic vasopressin agonists
US6547395B1 (en) * 1998-02-06 2003-04-15 Wavefront Sciences, Inc. Methods of measuring moving objects and reducing exposure during wavefront measurements
WO2000046224A2 (en) 1999-02-04 2000-08-10 American Home Products Corporation Tricyclic pyridine n-oxides vasopressin agonists
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
CN1323076C (zh) 2001-11-16 2007-06-27 安斯泰来制药有限公司 4,4－二氟－1,2,3,4－四氢－5h－1－苯并氮杂䓬衍生物或其盐
WO2004096775A1 (ja) 2003-04-28 2004-11-11 Astellas Pharma Inc. ４，４－ジフルオロ－１，２，３，４－テトラヒドロ－５ｈ－１－ベンゾアゼピン誘導体又はその塩

Also Published As

Publication number Publication date
KR20060007402A (ko) 2006-01-24
US20060122170A1 (en) 2006-06-08
NO333505B1 (no) 2013-06-24
US7807664B2 (en) 2010-10-05
DK1619185T3 (da) 2011-07-18
NO20055602D0 (no) 2005-11-25
CA2521492A1 (en) 2004-11-11
KR100882154B1 (ko) 2009-02-06
NO20055602L (no) 2006-01-24
US20070167429A1 (en) 2007-07-19
AU2004234258B2 (en) 2009-04-09
AU2004234258A1 (en) 2004-11-11
PL1619185T3 (pl) 2011-12-30
WO2004096775A1 (ja) 2004-11-11
BRPI0409718A (pt) 2006-05-02
ATE512951T1 (de) 2011-07-15
NZ542815A (en) 2009-01-31
RU2005136863A (ru) 2006-04-20
SI1619185T1 (sl) 2011-09-30
RU2326868C2 (ru) 2008-06-20
EP1619185B1 (en) 2011-06-15
US7183271B2 (en) 2007-02-27
CA2521492C (en) 2010-09-21
EP1619185A1 (en) 2006-01-25
PT1619185E (pt) 2011-08-25
EP1619185A4 (en) 2008-07-23
IL171332A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
TW200728307A (en) Novel spirochromanone derivatives
MX2009004096A (es) Metabolitos de talarozol.
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
MXPA05009985A (es) Ligandos de receptores de canabinoides.
JO2282B1 (en) Oxazole derivatives
GB9914486D0 (en) Medicaments
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
IL164974A0 (en) Novel compounds and their use
SI1696905T1 (sl) Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
BR0211972A (pt) Composição oftálmica
WO2006113552A3 (en) Cyanoarylamines
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
MXPA05011521A (es) Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MXPA05006450A (es) Nuevo derivado de 2,4-diamino-1,3,5-triazina.
DE60114640D1 (en) Antithrombosemittel
GB0212410D0 (en) Organic compounds
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
GB0218816D0 (en) Antitumoral analogs of lamellarins
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
MY135359A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FG Grant or registration